Weinstock Leonard B, Brook Jill B, Myers Trisha L, Goodman Brent
Medicine, Washington University, Saint Louis, Missouri, USA.
Gastroenterology, Specialists in Gastroenterology, Saint Louis, MO, USA.
BMJ Case Rep. 2018 Jan 11;2018:bcr-2017-221405. doi: 10.1136/bcr-2017-221405.
A patient with severe postural orthostatic tachycardia syndrome (POTS) and mast cell activation syndrome (MCAS) received immunotherapy with low-dose naltrexone (LDN) and intravenous immunoglobulin (IVIg) and antibiotic therapy for small intestinal bacterial overgrowth (SIBO). A dramatic and sustained response was documented. The utility of IVIg in autoimmune neuromuscular diseases has been published, but clinical experience with POTS is relatively unknown and has not been reported in MCAS. As a short-acting mu-opioid antagonist, LDN paradoxically increases endorphins which then bind to regulatory T cells which regulate T-lymphocyte and B-lymphocyte production and this reduces cytokine and antibody production. IVIg is emerging as a promising therapy for POTS. Diagnosis and treatment of SIBO in POTS is a new concept and appears to play an important role.
一名患有严重体位性直立性心动过速综合征(POTS)和肥大细胞活化综合征(MCAS)的患者接受了低剂量纳曲酮(LDN)免疫疗法、静脉注射免疫球蛋白(IVIg)以及针对小肠细菌过度生长(SIBO)的抗生素治疗。记录到了显著且持续的反应。IVIg在自身免疫性神经肌肉疾病中的应用已有报道,但POTS的临床经验相对较少,且在MCAS中尚未见报道。作为一种短效μ-阿片受体拮抗剂,LDN反而会增加内啡肽,内啡肽随后与调节性T细胞结合,调节性T细胞可调节T淋巴细胞和B淋巴细胞的产生,从而减少细胞因子和抗体的产生。IVIg正逐渐成为治疗POTS的一种有前景的疗法。POTS中SIBO的诊断和治疗是一个新概念,似乎起着重要作用。